Back to search

Peptide record

TPDB07268

Temporin-La Antibacterial Anticancer Antifungal Toxicity Tumor-homing Peptides standard

13 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB07268

Peptide_Name

Temporin-La

Activity

Antibacterial Anticancer Antifungal Toxicity Tumor-homing Peptides

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb dbAMP ToxinPred 3.0 StackTHPred TumorHoPe2.0

Sequence_Type

standard

Has_Modification No

Description A 13-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.

Sequence

LLRHVVKILEKYL

FASTA

>TPDB07268|Antibacterial;Anticancer;Antifungal;Toxicity;Tumor-homing Peptides|length=13
LLRHVVKILEKYL

Formula C78H134N20O17

Absent Amino Acids ANDCQGMFPSTW

Common Amino Acids L

Mass 1624.05

PI 10.19

Basic Residues 4

Acidic Residues 1

Hydrophobic Residues 8

Net Charge +2

Boman Index 2.42

Hydrophobicity 0.600

Aliphatic Index 194.62

Half Life

Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 1490

Absorbance 280nm 91.75

Polar Residues 1

number

Amino Acid Distribution

A: 0 R: 1 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 0 H: 1 I: 1 L: 4 K: 2 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 2

Length

Formula

C78H134N20O17

Mass

1624.05

10.19

Net Charge

Boman Index

2.42

Hydrophobicity

0.600

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

Temporins family

Evidence 1 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 2.5 µg/mL

Target

Target Organism Staphylococcus aureus ATCC 25923

Source & Reference

Database Source dbAMP

Other

Source Activity Label	Source Definition
Antibacterial	dbAMP classified as Antibacterial under the Anti-bacterial function class.

Evidence Text

active against S. aureus ATCC 25923 (MIC 2.5 ug/ml), S. suis 2 CVCC 606 (MIC 15.6 ug/ml), C. albicans ATCC10231 (MIC 31.25 ug/ml), Salmonella

Evidence 2 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 15.6 µg/mL

Target

Target Organism S. suis 2 CVCC 606

Source & Reference

Database Source dbAMP

Other

Evidence Text

active against S. aureus ATCC 25923 (MIC 2.5 ug/ml), S. suis 2 CVCC 606 (MIC 15.6 ug/ml), C. albicans ATCC10231 (MIC 31.25 ug/ml), Salmonella ATCC 20020 (MIC 15.6 ug/ml), P. aeru

Evidence 3 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 31.25 µg/mL

Target

Target Organism Candida albicans ATCC10231

Source & Reference

Database Source dbAMP

Other

Evidence Text

active against S. aureus ATCC 25923 (MIC 2.5 ug/ml), S. suis 2 CVCC 606 (MIC 15.6 ug/ml), C. albicans ATCC10231 (MIC 31.25 ug/ml), Salmonella ATCC 20020 (MIC 15.6 ug/ml), P. aeruginosa ATCC 227853 (MIC 60 ug/ml). Also,

Evidence 4 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 60 µg/mL

Target

Target Organism Pseudomonas aeruginosa ATCC 227853

Source & Reference

Database Source dbAMP

Other

Evidence Text

ug/ml), C. albicans ATCC10231 (MIC 31.25 ug/ml), Salmonella ATCC 20020 (MIC 15.6 ug/ml), P. aeruginosa ATCC 227853 (MIC 60 ug/ml). Also, B-subtitlis (MIC >64 uM), M. luteus (MIC 8 uM), E. coli (MIC 8 uM), P. vulgaris (M

Evidence 5 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 8 µM

Target

Target Organism M. luteus

Source & Reference

Database Source dbAMP

Other

Evidence Text

IC 15.6 ug/ml), P. aeruginosa ATCC 227853 (MIC 60 ug/ml). Also, B-subtitlis (MIC >64 uM), M. luteus (MIC 8 uM), E. coli (MIC 8 uM), P. vulgaris (MIC 16 uM) ( Yang et al., 2023 .

Evidence 6 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 8 µM

Target

Target Organism Escherichia coli

Source & Reference

Database Source dbAMP

Other

Evidence Text

uginosa ATCC 227853 (MIC 60 ug/ml). Also, B-subtitlis (MIC >64 uM), M. luteus (MIC 8 uM), E. coli (MIC 8 uM), P. vulgaris (MIC 16 uM) ( Yang et al., 2023 .

Evidence 7 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 16 µM

Target

Target Organism P. vulgaris

Source & Reference

Database Source dbAMP

Other

Evidence Text

(MIC 60 ug/ml). Also, B-subtitlis (MIC >64 uM), M. luteus (MIC 8 uM), E. coli (MIC 8 uM), P. vulgaris (MIC 16 uM) ( Yang et al., 2023 .

Evidence 8 Activity

Activity

Activity Raw

57.62 Inhibition ratio at 50 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Colorectal Cancer

Cell Line SW-1116

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 9 Activity

Activity

Activity Raw

52.77 Inhibition ratio at 50 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Liver Cancer

Cell Line SMMC-7721

Tissue Affected Liver

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 10 Activity

Activity

Activity Raw

52.32 Inhibition ratio at 50 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 11 Activity

Activity

Activity Raw

50.90 Inhibition ratio at 50 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Liver Cancer

Cell Line HepG-2

Tissue Affected Liver

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 12 Activity

Activity

Activity Raw

48.19 Inhibition ratio at 50 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Gastric Cancer

Cell Line BGC-823

Tissue Affected Stomach

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 13 Activity

Activity

Activity Raw

45.62 Inhibition ratio at 50 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 14 Activity

Activity

Activity Raw

37.22 Inhibition ratio at 50 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Liver Cancer

Cell Line HL7702

Tissue Affected Liver

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 15 Activity

Activity

Activity Raw

30.82 Inhibition ratio at 50 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Renal Cancer

Cell Line HEK-293T

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 16 Activity

Activity

Activity Raw

24.15Inhibition ratio at 50 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Breast Cancer

Cell Line MEC

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 17 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 2.5 µg/mL

Target

Target Organism Staphylococcus aureus ATCC 25923

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Source Activity Label	Source Definition
Antifungal	dbAMP classified under the Anti-fungal function class.

Evidence Text

active against S. aureus ATCC 25923 (MIC 2.5 ug/ml), S. suis 2 CVCC 606 (MIC 15.6 ug/ml), C. albicans ATCC10231 (MIC 31.25 ug/ml), Salmonella

Evidence 18 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 15.6 µg/mL

Target

Target Organism S. suis 2 CVCC 606

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Evidence Text

active against S. aureus ATCC 25923 (MIC 2.5 ug/ml), S. suis 2 CVCC 606 (MIC 15.6 ug/ml), C. albicans ATCC10231 (MIC 31.25 ug/ml), Salmonella ATCC 20020 (MIC 15.6 ug/ml), P. aeru

Evidence 19 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 31.25 µg/mL

Target

Target Organism Candida albicans ATCC10231

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Evidence Text

Evidence 20 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 60 µg/mL

Target

Target Organism Pseudomonas aeruginosa ATCC 227853

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Evidence Text

Evidence 21 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 8 µM

Target

Target Organism M. luteus

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Evidence Text

IC 15.6 ug/ml), P. aeruginosa ATCC 227853 (MIC 60 ug/ml). Also, B-subtitlis (MIC >64 uM), M. luteus (MIC 8 uM), E. coli (MIC 8 uM), P. vulgaris (MIC 16 uM) ( Yang et al., 2023 .

Evidence 22 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 8 µM

Target

Target Organism Escherichia coli

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Evidence Text

uginosa ATCC 227853 (MIC 60 ug/ml). Also, B-subtitlis (MIC >64 uM), M. luteus (MIC 8 uM), E. coli (MIC 8 uM), P. vulgaris (MIC 16 uM) ( Yang et al., 2023 .

Evidence 23 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 16 µM

Target

Target Organism P. vulgaris

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Evidence Text

(MIC 60 ug/ml). Also, B-subtitlis (MIC >64 uM), M. luteus (MIC 8 uM), E. coli (MIC 8 uM), P. vulgaris (MIC 16 uM) ( Yang et al., 2023 .

Evidence 24 Activity

Activity

Activity Endpoint 0% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 250 µg/mL

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

0% Hemolysis | 250 | µg/mL | target cell: Rabbit erythrocytes

Target

Target Cell Rabbit erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Effects of Two Novel Peptides from Skin of Lithobates Catesbeianus on Tumor Cell Morphology and Proliferation | Molecular Cloning - Selected Applications in Medicine and Biology | 2011

Evidence 25 Activity

Activity

Activity Endpoint 37.22±0.85% Inhibition

Detail Source Activity Toxicity

Activity Measurement 50 µg/mL

Toxicity Type Cytotoxic

Toxicity Raw

37.22±0.85% Inhibition | 50 | µg/mL | target cell: Human hepatocyte cells HL-7702 (L02)

Target

Target Cell Human hepatocyte cells HL-7702 (L02)

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012

Evidence 26 Activity

Activity

Activity Endpoint 30.82±0.95% Inhibition

Detail Source Activity Toxicity

Activity Measurement 50 µg/mL

Toxicity Type Cytotoxic

Toxicity Raw

30.82±0.95% Inhibition | 50 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Target Cell Human embryonic kidney HEK293T cells

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012

Evidence 27 Activity

Activity

Activity Endpoint 24.15±16.97% Inhibition

Detail Source Activity Toxicity

Activity Measurement 50 µg/mL

Toxicity Type Cytotoxic

Toxicity Raw

24.15±16.97% Inhibition | 50 | µg/mL | target cell: Bovine mammary epithelial cells

Target

Target Cell Bovine mammary epithelial cells

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012

Evidence 28 Activity

Activity

Activity Endpoint 18.17±1.04% Inhibition

Detail Source Activity Toxicity

Activity Measurement 50 µg/mL

Toxicity Type Cytotoxic

Toxicity Raw

18.17±1.04% Inhibition | 50 | µg/mL | target cell: Human PBMC

Target

Target Cell Human PBMC

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012

Evidence 29 Activity

Activity

Detail Source Activity Toxicity

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

Hemolytic_activity: Showed no hemolytic activity against rabbit erythrocytes and human erythrocytes at 250 µg/ml | Cytotoxicity: Showed little effects on the proliferation of the 293T human embryonic kidney cell line, MECs, and human lymphomonocytes at concentrations of less than 50 µg/ml

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

J Pept Sci. 2012 Jul 18(7):476-86.